We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.
Click Target For More Info
| Description | Progress | |||||
|---|---|---|---|---|---|---|
| Target | Type | Indication | Discovery | Lead ID | Lead Optimisation | Preclinical |
| MC2 | GPCR | Orphan endocrine disorders | ||||
| Gasdermin | Intracellular complexes | Broad immunology | ||||
| GPR65 | GPCR | IBD | ||||
| SLC15A4 | Solute carriers | Lupus and other IFN-opathies | ||||
| KCC2 | Solute carriers | Epilepsy including rare epilepsy disorders | ||||
MC2
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
Gasdermin
First-in-class Gasdermin D inhibitors – a pipeline in a product.
GPR65
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.
SLC15A4
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
KCC2
First-in-class solute carrier activator reducing seizures in epilepsy including rare epilepsies